|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for F3 |
 Gene summary |
| Basic gene Info. | Gene symbol | F3 |
| Gene name | coagulation factor III (thromboplastin, tissue factor) | |
| Synonyms | CD142|TF|TFA | |
| Cytomap | UCSC genome browser: 1p22-p21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001178096.1, NM_001993.4, | |
| Description | tissue factor | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 134390 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000117525 | ||
| HPRD : 00603 | ||
| Vega : OTTHUMG00000010716 | ||
| Protein | UniProt: P13726 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_F3 | |
| BioGPS: 2152 | ||
| Pathway | NCI Pathway Interaction Database: F3 | |
| KEGG: F3 | ||
| REACTOME: F3 | ||
| Pathway Commons: F3 | ||
| Context | iHOP: F3 | |
| ligand binding site mutation search in PubMed: F3 | ||
| UCL Cancer Institute: F3 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0001938 | positive regulation of endothelial cell proliferation | 17898544 | GO:0002541 | activation of plasma proteins involved in acute inflammatory response | 17469850 | GO:0006919 | activation of cysteine-type endopeptidase activity involved in apoptotic process | 17898544 | GO:0010641 | positive regulation of platelet-derived growth factor receptor signaling pathway | 17991872 | GO:0045766 | positive regulation of angiogenesis | 17898544 |
| Top |
| Ligand binding site mutations for F3 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | F172 | S174N | COAD | 1 | F172 | S174R | LUSC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for F3 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | F172 | S174N | -0.79415976 | F172 | S174R | -0.33859627 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for F3 from PDB |
| Top |
| Differential gene expression and gene-gene network for F3 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for F3 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0012739 | Disseminated Intravascular Coagulation | 14 | Biomarker |
| umls:C0023487 | Leukemia, Promyelocytic, Acute | 11 | Biomarker |
| umls:C0040053 | Thrombosis | 7 | AlteredExpression, Biomarker, GeneticVariation |
| umls:C1458155 | Breast Neoplasms | 6 | AlteredExpression, Biomarker |
| umls:C0023890 | Liver Cirrhosis | 3 | AlteredExpression, Biomarker |
| umls:C0151744 | Myocardial Ischemia | 2 | Biomarker, GeneticVariation |
| umls:C0027726 | Nephrotic Syndrome | 2 | Biomarker |
| umls:C0034155 | Purpura, Thrombotic Thrombocytopenic | 1 | Biomarker |
| umls:C0042487 | Venous Thrombosis | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for F3 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved | DB00036 | Coagulation factor VIIa Recombinant Human | Biotech |  |
| Experimental | DB07207 | 2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE | Small molecule |  |
| Experimental | DB07247 | [2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA | Small molecule |  |
| Experimental | DB08232 | {5-(5-AMINO-1H-PYRROLO[3,2-B]PYRIDIN-2-YL)-6-HYDROXY-3'-NITRO-BIPHENYL-3-YL]-ACETIC ACID | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of F3 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of F3 |
| Multiple alignments for P13726 in multiple species |
| LBS | AA sequence | # species | Species | F172 | RRNNTFLSLRD | 1 | Homo sapiens | F172 | RKNGTFLTLRQ | 1 | Mus musculus | F172 | RANSAFLSLRD | 1 | Bos taurus | R163 | TVEDERTLVRR | 1 | Homo sapiens | R163 | VVKDSLTLVRK | 1 | Mus musculus | R163 | TVQDARTLVRA | 1 | Bos taurus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |